Yuting Zhang

Yuting Zhang

Auto-generated profile, based on publicly available information

Yuting Zhang

Melbourne Institute: Applied Economic & Social Research, The University of Melbourne, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
IHInmaculada Hernandez
Inmaculada Hernandez
SBSeo Hyon Baik
Seo Hyon Baik
APAntonio Piñera
Antonio Piñera
YZYuting Zhang
Yuting Zhang
The Food and Drug Administration (FDA) approved dabigatran etexilate mesylate for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) in October 20101 based on the results of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.2 Quiz Ref ID The RE-LY trial did not find differences in the rates of major bleeding between treatments; however, dabigatran was superior to warfarin sodium in the prevention of stroke. In addition, dabigatran etexilate mesylate, 150 mg, was associated with a higher risk of gastrointestinal bleeding but a lower rate of intracranial hemorrhage compared with warfarin.

1 June 2018 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
IHInmaculada Hernandez
Inmaculada Hernandez
MHMeiqi He
Meiqi He
MBMaria M. Brooks
Maria M. Brooks
YZYuting Zhang
Yuting Zhang
Between 1999 and 2015, opioid-related overdoses nearly tripled in the United States, and in 2015 alone more than 33 000 deaths were due to opioid-related overdoses.1,2 It is estimated that 30% of fatal opioid-related overdoses involve the concurrent use of benzodiazepines.3 The concurrent administration of benzodiazepines increases the risk of opioid-related overdose because of the combination of their depressant effects on the central nervous system’s controls for respiration.4 For this reason, the Centers for Disease Control and Prevention recommends against their concurrent use.4 Despite this recommendation, the concurrent use of opioids and benzodiazepines has increased by more than 40% in the last 12 years,5 and in 2013 more than 20% of patients taking opioids used benzodiazepines concurrently.6,7

1 November 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
YZYuting Zhang
Yuting Zhang
SBSeo Hyon Baik
Seo Hyon Baik
AFA. Mark Fendrick
A. Mark Fendrick
KBKatherine Baicker
Katherine Baicker
Wide geographic variation in health care spending has generated both concern about inefficiency and policy debate about geographic-based payment reform. Evidence regarding variation has focused on hospital referral regions (HRRs), which incorporate numerous local hospital service areas (HSAs). If there is substantial variation across local areas within HRRs, then policies focusing on HRRs may be poorly targeted. Using prescription drug and medical claims data from a 5% random sample of Medicare beneficiaries from 2006 through 2009, we compared variation in health care spending and utilization among 306 HRRs and 3436 HSAs. We adjusted for beneficiary-level demographic characteristics, insurance status, and clinical characteristics. There was substantial local variation in health care (drug and nondrug) utilization and spending. Furthermore, many of the low-spending HSAs were located in high-spending HRRs, and many of the high-spending HSAs were in low-spending HRRs. For drug spending, only 50.7% of the HSAs located within the borders of the highest-spending quintile of HRRs were in the highest-spending quintile of HSAs; conversely, only 51.5% of the highest-spending HSAs were located within the borders of the highest-spending HRRs. Similar patterns were observed for nondrug spending. The effectiveness of payment reforms in reducing overutilization while maintaining access to high-quality care depends on the effectiveness of targeting. Our analysis suggests that HRR-based policies may be too crudely targeted to promote the best use of health care resources. (Funded by the Institute of Medicine and others.)

1 July 2014 in Vaccine
Verified
Journal Article
Closed access
ZHZhiyuan Hou
Zhiyuan Hou
CJChang Jie
Chang Jie
DYDahai Yue
Dahai Yue
HFHai Fang
Hai Fang
QMQingyue Meng
Qingyue Meng
YZYuting Zhang
Yuting Zhang

2 July 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
YZYuting Zhang
Yuting Zhang
JDJulie M. Donohue
Julie M. Donohue
JLJudith R. Lave
Judith R. Lave
GOGerald O'Donnell
Gerald O'Donnell
JNJoseph P. Newhouse
Joseph P. Newhouse
It is not known what effect the increased use of prescription drugs by enrollees in Medicare Part D has had on spending for other medical care. We compared spending for prescription drugs and other medical care 2 years before the implementation of Part D in January 2006 with such expenditures 2 years after the program's implementation in four groups of elderly beneficiaries: Medicare Advantage enrollees with stable, uncapped, employer-based drug coverage throughout the study period (no-cap group), those who had no previous drug coverage, and those who had previous limited benefits (with either a $150 or a $350 quarterly cap) before they were covered by Part D in 2006. Between December 2005 and December 2007, as compared with the increase in the no-cap group, the increase in total monthly drug spending was $41 higher (95% confidence interval [CI], $33 to $50) (74%) among enrollees with no previous drug coverage, $27 higher (95% CI, $20 to $34) (27%) among those with a previous $150 quarterly cap, and $13 higher (95% CI, $8 to $18) (11%) among those with a previous $350 cap. The use of both lipid-lowering and antidiabetic medications rose in the groups with no or minimal previous drug coverage. As compared with expenditures in the no-cap group, monthly medical expenditures (excluding drugs) were $33 lower (95% CI, $29 to $37) in the group with no previous coverage and $46 lower (95% CI, $29 to $63) in the group with a previous $150 quarterly cap, whereas medical spending was $30 higher (95% CI, $25 to $36) in the group with a previous $350 cap. Enrollment in Medicare Part D was associated with increased spending on prescription drugs. Groups that had no or minimal drug coverage before the implementation of Part D had reductions in other medical spending that approximately offset the increased spending on drugs, but medical spending increased in the group that had more generous previous coverage.

18 November 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
YZYuting Zhang
Yuting Zhang
KBKatherine Baicker
Katherine Baicker
JNJoseph P. Newhouse
Joseph P. Newhouse
To assess U.S. geographic variation in the management of medication in elderly patients, the authors examined performance on two quality measures: the use of medications considered to be high-risk for the elderly and potentially harmful drug–disease interactions.